What side effects are associated with this type of intervention?

Common treatments for heart failure include ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists. ACE inhibitors can cause cough, elevated blood potassium levels, and kidney dysfunction. Beta-blockers may lead to fatigue, bradycardia, and dizziness. Diuretics often result in electrolyte imbalances, dehydration, and increased urination. Aldosterone antagonists can cause hyperkalemia and renal impairment. These side effects should be monitored by healthcare providers to ensure safe and effective management of heart failure.

What prior FDA approvals exist?

The FDA has approved several medications for the treatment of heart failure, including beta-blockers like carvedilol and metoprolol, which help reduce the heart's workload and improve survival. ACE inhibitors such as enalapril and lisinopril, and ARBs like losartan and valsartan, are also commonly used to relax blood vessels and lower blood pressure, thereby improving heart function. Additionally, newer medications like sacubitril/valsartan (an ARNI) and SGLT2 inhibitors such as dapagliflozin have shown benefits in heart failure management. These treatments align with the goals of the iPeer2Peer program, which aims to support disease self-management and improve outcomes in heart failure patients.

What other types of research exist?

Promising alternatives to the iPeer2Peer program for heart failure patients in 2024 include: 1) Telemedicine platforms offering remote monitoring and virtual consultations, 2) Mobile health applications providing personalized disease management plans and real-time health tracking, 3) Online support groups and forums facilitated by healthcare professionals, and 4) AI-driven chatbots and virtual health assistants for continuous patient engagement and education.

← Back to Search

Behavioral Intervention

iPeer2Peer Mentorship for Teen Heart Failure (iP2P HF Trial)

N/A

Recruiting

Led By Samantha J Anthony, PhD

Research Sponsored by The Hospital for Sick Children

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up study completion, an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial tests an online program where young adults mentor younger teens with the same health condition. The goal is to help teens manage their condition better by learning from someone who has been through similar experiences. Mentors and mentees will connect over several months using video calls and text messages.

Who is the study for?

This trial is for teens with heart failure aged 12-17 who are at least 4 months post-diagnosis, and young adults aged 18-25 as mentors. Mentees must commit to regular communication with a mentor over 15 weeks. Mentors need good communication skills, emotional stability, and willingness to train and support mentees. Excluded are those in other peer programs or with significant cognitive impairments or active psychological disorders.

What is being tested?

The iP2P program is being tested to see if it helps teen heart failure patients manage their condition better through online peer mentorship. Participants will be randomly assigned to start the program immediately or after a waiting period (waitlist). They'll use video calls and texts for support over a period of 15 weeks.

What are the potential side effects?

Since this trial involves an educational intervention rather than medication, traditional physical side effects aren't expected. However, participants may experience emotional discomfort due to discussing personal health issues.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Acceptability (Mentees)

Acceptability (Mentors)

Adoption (Mentees)

+5 more

Secondary study objectives

Adherence (Mentees)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: iPeer2Peer ProgramExperimental Treatment1 Intervention

Group II: Standard of Care Waitlist Control GroupActive Control1 Intervention

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for heart failure include ACE inhibitors, which relax blood vessels and reduce the workload on the heart; beta-blockers, which slow the heart rate and decrease blood pressure to improve heart function; diuretics, which help remove excess fluid from the body to reduce swelling and ease breathing; and aldosterone antagonists, which block the effects of aldosterone to prevent fluid retention and further heart damage. These treatments are crucial for heart failure patients as they help manage symptoms, improve quality of life, and reduce hospitalizations. Programs like iPeer2Peer that focus on peer support and disease self-management can enhance adherence to these treatments and empower patients to take an active role in their care.